CD274 and neoplasm: By binding to PD-L1, Avelumab blocks its interaction with the PD-1 receptor on T-cells, thereby preventing the deactivation of the anti-tumor immune response and effectively allowing cytotoxic T-lymphocytes to kill cancer cells [11].